The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer
Open accessAbstract
Typical regimens for advanced metastatic stage IIIB/IV nonsmall cell lung cancer (NSCLC) consist of multiple lines of treatment. We present an adaptive reinforcement learning approach to discover optimal individualized treatment regimens from a specially designed clinical trial (a "clinical reinforcement trial") of an experimental treatment for patients with advanced NSCLC who have not been treated previously with systemic therapy. In addition to the complexity of the problem of selecting optimal compounds for first- and second-line treatments based on prognostic factors, another primary goal is to determine the optimal time to initiate second-line therapy, either immediately or delayed after induction therapy, yielding the longest overall survival time. A reinforcement learning method called Q-learning is utilized, which involves learning an optimal regimen from patient data generated from the clinical reinforcement trial. Approximating the Q-function with time-indexed parameters can be achieved by using a modification of support vector regression that can utilize censored data. Within this framework, a simulation study shows that the procedure can extract optimal regimens for two lines of treatment directly from clinical data without prior knowledge of the treatment effect mechanism. In addition, we demonstrate that the design reliably selects the best initial time for second-line therapy while taking into account the heterogeneity of NSCLC across patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Cited by
Estimating Individualized Treatment Rules Using Outcome Weighted Learning
Zhao, Y., Zeng, D., Rush, A. J., & Kosorok, M. R. (2012) · Journal of the American Statistical Association · doi:10.1080/01621459.2012.695674 · Cited by 739
Self-citationReinforcement Learning in Healthcare: A Survey
Yu, C., Liu, J., Nemati, S., & Yin, G. (2023) · ACM Computing Surveys · doi:10.1145/3477600 · Cited by 628
Machine learning in cardiovascular medicine: are we there yet?
Shameer, K., Johnson, K. W., Glicksberg, B. S., Dudley, J. T., & Sengupta, P. P. (2018) · Heart · doi:10.1136/heartjnl-2017-311198 · Cited by 555
Reinforcement Learning based Recommender Systems: A Survey
Afsar, M. M., Crump, T., & Far, B. (2023) · ACM Computing Surveys · doi:10.1145/3543846 · Cited by 502
Estimating treatment effect heterogeneity in randomized program evaluation
Imai, K., & Ratkovic, M. (2013) · The Annals of Applied Statistics · doi:10.1214/12-aoas593 · Cited by 480
Metadata
- Authors
- Zhao, Y., Zeng, D., Socinski, M. A., & Kosorok, M. R.
- Venue
- Biometrics
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-03-08
- Volume
- 67
- Issue
- 4
- Pages
- 1422-1433
- ISSN
- 0006-341X (ISSN-L)
- OpenAlex
- W2049655669
- Cited by
- 208
- References
- 3
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer. https://app.cochat.ai/papers/10.1111/j.1541-0420.2011.01572.x
- The paper
- Zhao, Y., Zeng, D., Socinski, M. A., & Kosorok, M. R. (2011). Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer. Biometrics. https://doi.org/10.1111/j.1541-0420.2011.01572.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.